Antifungal prophylaxis and pre-emptive therapy.

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Mycology

Background:

• Fungal infections are increasingly recognized as a significant cause of illness and death in hospitalized patients.
• High mortality rates associated with fungal infections necessitate preventative strategies, particularly in intensive care units (ICUs).

Purpose of the Study:

• To evaluate the efficacy and safety of antifungal chemoprophylaxis in high-risk surgical patients.
• To determine the role of triazoles in preventing invasive candidiasis in intensive care unit (ICU) settings.

Main Methods:

• Review of available evidence on antifungal prophylaxis in surgical and ICU patients.
• Analysis of studies comparing triazoles (fluconazole, itraconazole) with placebo for Candida prevention.

Main Results:

• Triazoles demonstrated a reduction in Candida colonization and potentially infection compared to placebo in specific high-risk patient groups.
• Evidence primarily comes from studies involving patients with tertiary peritonitis requiring multiple surgeries.

Conclusions:

• Antifungal prophylaxis with triazoles should be cautiously applied, reserved for high-risk patients susceptible to invasive candidiasis, such as those in surgical ICUs.
• A pre-emptive treatment strategy, initiating antifungals before confirmed infection, shows promise for safety and effectiveness.